Regulatory News:
Philip Morris International Inc.’s (NYSE / Euronext Paris: PM) Chief
Financial Officer, Jacek Olczak, will address investors today at the
Barclays Global Consumer Staples Conference in Boston.
The presentation and Q&A session are being webcast live, in a
listen-only mode, beginning at approximately 1:30 p.m. ET, at www.pmi.com/webcasts.
Highlights of the presentation include updates on the company’s July
year-to-date performance in key geographies, as well as the
commercialization and clinical assessment of its reduced-risk product, iQOS.
“Our third quarter is off to a positive start, and this augurs well for
the balance of the year. Robust fundamentals have driven favorable
cigarette volume and share performance,” said Jacek Olczak, Chief
Financial Officer. “iQOS is performing at or above our
expectations and we are very encouraged by the results of our clinical
studies thus far.”
An archived copy of the webcast will be available at www.pmi.com/webcasts
until 5:00 p.m. ET on Wednesday, October 7, 2015. Remarks and slides
will also be available at www.pmi.com/presentations.
Philip Morris International Inc.
Philip Morris International Inc. (PMI) is the leading international
tobacco company, with six of the world's top 15 international brands,
including Marlboro, the number one cigarette brand worldwide.
PMI's products are sold in more than 180 markets. In 2014, the company
held an estimated 15.6% share of the total international cigarette
market outside of the U.S., or 28.6% excluding the People's Republic of
China and the U.S. For more information, see www.pmi.com.
Reduced-Risk Products ("RRPs") is the term the company uses to refer to
products with the potential to reduce individual risk and population
harm in comparison to smoking combustible tobacco products such as
cigarettes. One of our strategic priorities is to develop, assess and
commercialize a portfolio of innovative RRPs. Our RRPs are in various
stages of development and commercialization, and we are conducting
extensive and rigorous scientific studies to determine whether they
reduce exposure to harmful and potentially harmful constituents and
ultimately reduce disease risk, compared to cigarettes. Any claims we
make are based on a full set of data from the relevant scientific
studies and may also be subject to government review and approval, as is
the case in the U.S. today.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908006124/en/
Copyright Business Wire 2015